Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Discovery and development of purine-scaffold Hsp90 inhibitors.

Chiosis G.

Curr Top Med Chem. 2006;6(11):1183-91. Review.

PMID:
16842155
2.

Development of purine-scaffold small molecule inhibitors of Hsp90.

Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N.

Curr Cancer Drug Targets. 2003 Oct;3(5):371-6. Review.

PMID:
14529388
3.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
4.
5.

Hsp90: a novel target for cancer therapy.

Solit DB, Rosen N.

Curr Top Med Chem. 2006;6(11):1205-14. Review.

PMID:
16842157
6.

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P.

Expert Opin Biol Ther. 2002 Jan;2(1):3-24. Review.

PMID:
11772336
7.

Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?

Isaacs JS.

Expert Opin Investig Drugs. 2005 Jun;14(6):569-89. Review.

PMID:
16004589
8.

Altered Hsp90 function in cancer: a unique therapeutic opportunity.

Bagatell R, Whitesell L.

Mol Cancer Ther. 2004 Aug;3(8):1021-30. Review.

9.

Emerging Hsp90 inhibitors: from discovery to clinic.

Chiosis G, Rodina A, Moulick K.

Anticancer Agents Med Chem. 2006 Jan;6(1):1-8. Review.

PMID:
16475922
10.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

11.

Recent advances in Hsp90 inhibitors as antitumor agents.

Messaoudi S, Peyrat JF, Brion JD, Alami M.

Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. Review.

PMID:
18855578
12.

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

Workman P, Burrows F, Neckers L, Rosen N.

Ann N Y Acad Sci. 2007 Oct;1113:202-16. Epub 2007 May 18. Review.

PMID:
17513464
13.

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

Workman P.

Cancer Lett. 2004 Apr 8;206(2):149-57. Review.

PMID:
15013520
14.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024
15.

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.

16.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
17.

HSP90 inhibitors: current development and potential in cancer therapy.

Sidera K, Patsavoudi E.

Recent Pat Anticancer Drug Discov. 2014 Jan;9(1):1-20. Review.

PMID:
23312026
18.

Effectiveness of hsp90 inhibitors as anti-cancer drugs.

Xiao L, Lu X, Ruden DM.

Mini Rev Med Chem. 2006 Oct;6(10):1137-43. Review.

PMID:
17073714
19.

Overview: translating Hsp90 biology into Hsp90 drugs.

Workman P.

Curr Cancer Drug Targets. 2003 Oct;3(5):297-300. Review.

PMID:
14529382
20.

Supplemental Content

Support Center